Company
Taysha Gene Therapies, Inc. (TSHA)
Standardized SEC financial data for Taysha Gene Therapies, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001806310 · NASDAQ · Biological Products, (No Diagnostic Substances).
Operating margin
-1000.0%
Net margin
-1000.0%
Revenue growth (YoY)
17.3%
Return on equity
-44.1%
Free cash flow
-$93.8M
Debt / equity
0.20×
Current ratio
12.23×
EPS (diluted)
$-0.34
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $2.5M | $15.5M | $8.3M | $9.8M |
| R&D expense |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $251.3M | $149.1M | $87.9M | $143.9M | $139.0M | $319.8M |
| Total current assets |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$30.7M | -$117.0M | -$88.4M | -$73.0M | -$81.2M | -$93.1M |
| Capital expenditures |
Get TSHA data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/TSHA/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/TSHA/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"